BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22014344)

  • 1. Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer.
    Higgins KA; Chino JP; Ready N; Onaitis MW; Berry MF; D'Amico TA; Kelsey CR
    J Thorac Cardiovasc Surg; 2011 Nov; 142(5):1175-9. PubMed ID: 22014344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.
    Stefani A; Alifano M; Bobbio A; Grigoroiu M; Jouni R; Magdeleinat P; Regnard JF
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):356-63. PubMed ID: 20381815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
    Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
    Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
    Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.
    Cerfolio RJ; Bryant AS; Jones VL; Cerfolio RM
    Eur J Cardiothorac Surg; 2009 Apr; 35(4):718-23; discussion 723. PubMed ID: 19233668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
    Pezzetta E; Stupp R; Zouhair A; Guillou L; Taffé P; von Briel C; Krueger T; Ris HB
    Eur J Cardiothorac Surg; 2005 Jun; 27(6):1092-8. PubMed ID: 15896624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.
    Carr SR; Schuchert MJ; Pennathur A; Wilson DO; Siegfried JM; Luketich JD; Landreneau RJ
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):390-7. PubMed ID: 22169444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience.
    Sarkaria IS; Iyoda A; Roh MS; Sica G; Kuk D; Sima CS; Pietanza MC; Park BJ; Travis WD; Rusch VW
    Ann Thorac Surg; 2011 Oct; 92(4):1180-6; discussion 1186-7. PubMed ID: 21867986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet.
    Fischer S; Darling G; Pierre AF; Sun A; Leighl N; Waddell TK; Keshavjee S; de Perrot M
    Eur J Cardiothorac Surg; 2008 Jun; 33(6):1129-34. PubMed ID: 18407511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.
    Higgins K; Chino JP; Marks LB; Ready N; D'Amico TA; Clough RW; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1462-7. PubMed ID: 19467798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical treatment of superior sulcus tumors: results and prognostic factors.
    Demir A; Sayar A; Kocaturk CI; Gunluoglu MZ; Akýn H; Metin M; Cansever L; Olcmen A; Dincer SI; Bedirhan MA; Gurses A
    Thorac Cardiovasc Surg; 2009 Mar; 57(2):96-101. PubMed ID: 19241311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer?
    Steger V; Spengler W; Hetzel J; Veit S; Walker T; Mustafi M; Friedel G; Walles T
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):880-5; discussion 885. PubMed ID: 22233799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy.
    Mansour Z; Kochetkova EA; Santelmo N; Ducrocq X; Quoix E; Wihlm JM; Massard G
    Ann Thorac Surg; 2008 Jul; 86(1):228-33. PubMed ID: 18573428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
    Rice TW; Adelstein DJ; Koka A; Tefft M; Kirby TJ; Van Kirk MA; Taylor ME; Olencki TE; Peereboom D; Budd GT
    Ann Thorac Surg; 1995 Sep; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
    Jaklitsch MT; Herndon JE; DeCamp MM; Richards WG; Kumar P; Krasna MJ; Green MR; Sugarbaker DJ
    J Surg Oncol; 2006 Dec; 94(7):599-606. PubMed ID: 17039491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.